Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...
Donald Trump has vowed to impose tariffs on countries that charge VAT, leaving Britain at risk of a £24bn blow to its economy ...
William Blair also issued estimates for Brown & Brown’s Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $4.22 EPS, Q1 2026 earnings at $1.41 EPS, Q2 2026 earnings at $1.11 EPS, Q3 2026 ...
CHICAGO, February 10, 2025--(BUSINESS WIRE)--William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named ...
William Blair downgraded Sprinklr (CXM) to Market Perform from Outperform without a price target after the company announced a 15% global workforce reduction. While expectations are low for the ...
William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as ...
William Blair last night initiated coverage of Rubrik (RBRK) with a Market Perform rating. While Rubrik’s growth runway “ooks long and its competitive moat durable,” the stock’s risk ...
On Monday, William Blair reaffirmed a Market Perform rating on Kenvue Inc (NYSE:KVUE), a consumer health company with a market capitalization of $38.69 billion. According to InvestingPro data ...
Amgen Inc. (NASDAQ:AMGN – Free Report) – Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th.
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a Outperform recommendation. As of January 29, 2025, the average one-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results